Dermira (DERM) received a Buy rating and a $14 price target from Mizuho Securities analyst Irina Rivkind Koffler today. The company’s shares closed yesterday at $8.98.
According to TipRanks.com, Koffler ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.0% and a 33.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dermira with a $22 average price target.
See today’s analyst top recommended stocks >>
Based on Dermira’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $64.83 million. In comparison, last year the company had a GAAP net loss of $59.25 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.
